Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex Pharmaceuticals and Orna Therapeutics have announced a three-year collaboration to develop next-generation gene therapies for sickle cell disease (SCD) and transfusion-dependent beta ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...